Table 1.
Baseline characteristics by vitamin D status
| Characteristic | Overall N = 1111 | Vitamin D replete (> 30ng/ml) N = 381 | Vitamin D insufficient (≤ 30ng/ml) N = 731 | p-value2 |
|---|---|---|---|---|
| Age | 0.039 | |||
| ≤ 65-years | 53 (48%) | 13 (34%) | 40 (55%) | |
| > 65-years | 58 (52%) | 25 (66%) | 33 (45%) | |
| Sex | 0.69 | |||
| Male | 70 (63%) | 23 (61%) | 47 (64%) | |
| Female | 41 (37%) | 15 (39%) | 26 (36%) | |
| Karnofsky Performance Status | 0.37 | |||
| ≥ 90 | 84 (79%) | 28 (74%) | 56 (81%) | |
| < 90 | 23 (21%) | 10 (26%) | 13 (19%) | |
| Unknown | 4 | 0 | 4 | |
| LBCL subtype | 0.026 | |||
| de novo LBCL | 62 (57%) | 15 (42%) | 47 (65%) | |
| transformed follicular lymphoma | 26 (24%) | 14 (39%) | 12 (17%) | |
| Other transformed low-grade | 20 (19%) | 7 (19%) | 13 (18%) | |
| Unknown | 3 | 2 | 1 | |
| Cell of origin | 0.83 | |||
| GCB | 49 (49%) | 17 (50%) | 32 (48%) | |
| Non-GCB | 52 (51%) | 17 (50%) | 35 (52%) | |
| Unknown | 10 | 4 | 6 | |
| Double/Triple hit | 11 (12%) | 5 (16%) | 6 (10%) | 0.50 |
| Unknown | 18 | 6 | 12 | |
| History of CNS disease | 21 (19%) | 5 (14%) | 16 (22%) | 0.32 |
| Unknown | 2 | 2 | 0 | |
| Primary refractory disease 3 | 32 (29%) | 9 (24%) | 23 (32%) | 0.36 |
| Unknown | 1 | 0 | 1 | |
| Previous autologous HCT | 27 (24%) | 8 (21%) | 19 (26%) | 0.56 |
| Previous allogeneic HCT | 7 (6%) | 3 (8%) | 4 (5%) | 0.69 |
| Number of previous lines | 0.61 | |||
| ≤ 3 lines | 50 (45%) | 16 (42%) | 34 (47%) | |
| 4 – 5 lines | 43 (39%) | 17 (45%) | 26 (36%) | |
| ≥ 6 lines | 18 (16%) | 5 (13%) | 13 (18%) | |
| Bulky disease at apheresis | 10 (9%) | 2 (5%) | 8 (11%) | 0.49 |
| Stage at Apheresis | 0.39 | |||
| ≤ II | 30 (27%) | 12 (32%) | 18 (25%) | |
| III – IV | 80 (73%) | 25 (68%) | 55 (75%) | |
| Unknown | 1 | 1 | 0 | |
| Bridging | 79 (72%) | 30 (79%) | 49 (68%) | 0.23 |
| Unknown | 1 | 0 | 1 | |
| Status at CAR-T infusion | 0.85 | |||
| CR | 9 (8%) | 3 (8%) | 6 (8%) | |
| PR | 25 (23%) | 10 (27%) | 15 (21%) | |
| SD/PD | 74 (69%) | 24 (65%) | 50 (70%) | |
| Unknown | 3 | 1 | 2 | |
| Time from diagnosis to CAR-T infusion (days) | 554 (316 – 924) | 687 (359 – 1,335) | 468 (314 – 803) | 0.12 |
| CAR-T Product | 0.049 | |||
| Axicabtagene ciloleucel | 60 (54%) | 22 (58%) | 38 (52%) | |
| Tisagenlecleucel | 44 (40%) | 11 (29%) | 33 (45%) | |
| Lisocabtagene maraleucel | 7 (6%) | 5 (13%) | 2 (3%) | |
| CAR-T costimulatory domain | 0.56 | |||
| 41BB | 51 (46%) | 16 (42%) | 35 (48%) | |
| CD28 | 60 (54%) | 22 (58%) | 38 (52%) |
1
Median (IQR); n (%)
2
Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test
3
Primary refractory disease pre-apheresis
LBCL, large B-cell lymphoma; GCB, germinal center B-cell; CNS, central nervous system; HCT, hematopoietic stem cell transplant; LDH, lactate dehydrogenase; CAR-T, chimeric antigen receptor T-cell therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease